Artificial neural network-based immune biomarker signature predicts pathological complete response to neoadjuvant chemotherapy in HER2-negative breast cancer
This study establishes a rigorously validated ANN-based immune gene signature for predicting response to neoadjuvant chemotherapy in HER2-negative breast cancer, providing a potential tool for pretreatment risk stratifictableation and individualized therapeutic decision-making.
Authors
- Shitang Nong
- Qiyuan Su
- Yulong Zhang (ORCID: https://orcid.org/0000-0003-3089-196X)
- Yanfei Ma
- Jiao Lu
- Dalang Fang
- Suai Deng
Institutions
- Affiliated Hospital of Youjiang Medical University for Nationalities (CN)
- Baise University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-03-04
- DOI
- https://doi.org/10.3389/fonc.2026.1781380
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00